Related Experiment Video

Updated: Feb 18, 2026

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS
09:20

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Published on: August 10, 2017

9.0K

Anti-cancer effects of naturally derived compounds targeting histone deacetylase 6-related pathways

Manon Lernoux1, Michael Schnekenburger1, Mario Dicato1

  • 1Laboratory of Molecular and Cellular Biology of Cancer, Kirchberg Hospital, 9, Edward Steichen Street, L-2540 Luxembourg, Luxembourg.

Pharmacological Research
|November 15, 2017
PubMed

Insights

Histone deacetylase 6 (HDAC6) is crucial in cancer development and progression. Modulating HDAC6 pathways with various compounds shows promise for anticancer therapies, offering new treatment strategies.

Area of Science:

  • Epigenetics
  • Molecular Biology
  • Oncology

Background:

  • Epigenetic alterations are key drivers of tumor development.
  • Histone deacetylase 6 (HDAC6) plays a significant role in cellular regulation and cancer progression.
  • HDAC6 influences multiple stages of tumor development, including initiation, promotion, progression, and metastasis.

Purpose of the Study:

  • To review the critical implications of HDAC6 in physiological and cancerous conditions.
  • To discuss the anticancer properties of compounds modulating HDAC6 pathways.

Main Methods:

  • Literature review of HDAC6's role in cancer.
  • Analysis of synthetic, natural, and natural-derived compounds targeting HDAC6.
  • Discussion of HDAC6-related pathways in cancer therapy.

Main Results:

  • HDAC6 is implicated in vital cellular processes and tumor progression.
  • Compounds targeting HDAC6 exhibit anticancer properties.
  • Modulation of HDAC6 pathways is a viable therapeutic strategy.

Conclusions:

  • HDAC6 is a significant target for cancer therapy.
  • Targeting HDAC6 offers potential for developing novel anticancer treatments.
  • Further research into HDAC6 modulation is warranted.
Keywords:
(−)-epigallocatechin-3-gallate (PubChem CID: 65064)20(S)-Rh2 (PubChem CID: 119307)ACY-1215 (PubChem CID: 53340666)ACY-241 (PubChem CID: 53340426)Cancer hallmarksCancer therapyFK228 (PubChem CID: 5352062)HDAC6HDAC6 inhibitorsLBH-589 (PubChem CID: 6918837)Natural compoundsPXD101 (PubChem CID: 6918638)SAHA (PubChem CID: 5311)aceroside VIII (PubChem CID: 21637600)butyrate (PubChem CID: 264)curcumin (PubChem CID: 969516)ellagic acid (PubChem CID: 5281855)genistein (PubChem CID: 5280961)salirepol (PubChem CID: 188287)sulforaphane (PubChem CID: 5350)trichostatin A (PubChem CID: 444732)tubacin (PubChem CID: 6675804)tubastatin A (PubChem CID: 49850262)ursodeoxycholic acid (PubChem CID: 31401)ursolic acid (PubChem CID: 64945)

More Related Videos

Assays for Validating Histone Acetyltransferase Inhibitors09:11

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

7.0K
Purification of H3 and H4 Histone Proteins and the Quantification of Acetylated Histone Marks in Cells and Brain Tissue09:43

Purification of H3 and H4 Histone Proteins and the Quantification of Acetylated Histone Marks in Cells and Brain Tissue

Published on: November 30, 2018

22.2K

Related Concept Videos

Spreading of Chromatin Modifications02:25

Spreading of Chromatin Modifications

The histone proteins in the nucleosomes are post-translationally modified (PTM) to increase or decrease access to DNA. The commonly observed PTMs are methylation, acetylation, phosphorylation, and ubiquitination of lysine amino acids in the histone H3 tail region. These histone modifications have specific meaning for the cell. Hence, they are called "histone code". The protein complex involved in histone modification is termed as "reader-writer" complex.
Writers
The writer...
9.6K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
8.8K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.8K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
4.0K
Histone Variants at the Centromere02:30

Histone Variants at the Centromere

Histone variants are the histone proteins with structural and sequence variations. These variants may be regarded as “mutant” forms that replace their canonical histone counterparts in the nucleosomes. Specific post-translational modifications on the histone variants enable further chromatin complexity and regulate tissue-specific gene expression. The most common histone variants are from histone H2A, H2B, and linker histone H1 families. However, several variants of histone H3...
5.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K